Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-23-002 (R61 Clinical Trial Not Allowed) R61 Clinical Trial Not Allowed 09/02/2023 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research RFA-CA-23-007 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 09/02/2023 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-23-010 (P50 Clinical Trial Optional) P50 Clinical Trial Optional 09/02/2023 Guillermo Marquez, Ph.D.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-23-003 (R33 Clinical Trial Not Allowed) R33 Clinical Trial Not Allowed 09/02/2023 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-23-008 (U54 Clinical Trials Optional) U54 09/02/2023 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) RFA-CA-23-011 Clinical Trial Optional 09/02/2023 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-23-006 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/02/2023 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-23-009 (P01 Clinical Trial Optional) P01 Clinical Trial Optional 09/02/2023 Guillermo Marquez, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/11/2023 Lynn Sorbara, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-314 (UH3 Clinical Trials Not Allowed) UH3 10/11/2023 Lynn Sorbara, Ph.D.